Table 3.
Markers differing significantly inpatients stratified by clinical subtype or treatment. Medians and interquartile ranges are shown.
| Marker | AAV Type | ANCA Specificity | ||||
|---|---|---|---|---|---|---|
| GPA(n = 127) | MPA (n= 36) | P* | PR3 (n=113) | MPO (n=50) | P* | |
| ICAM3 | 1.98 (1.47,2.71) | 2.79 (2.17,3.35) | 0.0001 | 1.98 (1.47,2.72) | 2.36 (1.89,2.96) | 0.003 |
| Thrombomodulin | 4.96 (3.54,6.53) | 6.97 (4.16,8.69) | 0.003 | 4.78 (3.49,5.97) | 6.94 (4.18,8.83) | <0.0001 |
| MMP9 | 368 (235,569) | 280 (180,370) | 0.014 | |||
|
| ||||||
| New or Established (Relapsing) AAV | Active Renal Disease | |||||
| New (n=77) | Relapsing (n=86) | P* | Yes (n=80) | No (n=83) | P* | |
|
| ||||||
| VEGF | 0.914 (0.592,1.33) | 0.430 (0.316,0.720) | <0.0001 | |||
| ICAM3 | 2.49 (2.04,2.98) | 1.78 (1.39,2.36) | <0.0001 | |||
| Thrombomodulin | 5.81 (4.44,7.86) | 4.41 (3.43,6.15) | <0.0001 | 6.94 (5.36,8.79) | 3.96 (3.32,4.78) | <0.0001 |
| MMP3 | 95.4 (52.2,163) | 50.9 (29.3,93.7) | <0.0001 | |||
| ESR(mm/hr) | 49 (26,79.5) | 34 (13,52) | 0.001 | |||
|
| ||||||
| Treatment at Screening | Glucocorticoids at Screening | |||||
| Yes (n=90) | No (n=73) | P* | Yes (n=79) | No (n=84) | P* | |
|
| ||||||
| VEGF | 0.461 (0.367,1.46) | 0.812 (0.539,1.28) | 0.001 | |||
| ICAM3 | 1.84 (1.43,2.42) | 2.43 (1.83,2.97) | 0.001 | 1.83 (1.43,2.42) | 2.37 (1.79,2.96) | 0.0003 |
| Thrombomodulin | 4.44 (3.43,6.18) | 5.87 (4.51,7.78) | 0.0003 | 4.41 (3.42,6.53) | 5.73 (4.18,7.27) | 0.001 |
| MMP1 | 23.0 (17.4,31.5) | 35.8 (22.6,60.4) | 0.0008 | 22.9 (18.1,30.4) | 32.3 (21.8,55.7) | 0.002 |
| ESR(mm/hr) | 31 (13,54) | 50 (25,75) | 0.006 | 29 (13,52) | 49 (25,70) | 0.008 |
Data are shown for markers showing significant differences (Wilcoxon tests) after adjustment for multiple comparisons. Data for all markers are shown in Supplementary Tables 2–4. All values in ng/ml except as noted for ESR. VEGF = vascular endothelial growth factor; ICAM = intercellular adhesion molecule; MMP = matrix metalloproteinase; ESR = erythrocyte sedimentation rate.
*
Comparing GPA to MPA, anti-PR3 to anti-MPO ANCA, new to relapsing AAV, presence or absence of active renal disease, and treatment (any immune-suppressive treatment, or specifically glucocorticoids), at screening.